Avalon BioVentures I, LP, 10% Owner at Janux Therapeutics, Inc. (JANX), sold 614,307 shares at $46.42 ($28.8M) on 2024-09-27, disclosed to the SEC on 2024-09-30.
Open-market sale of $28.8M JANX by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $46.78 | 9,592 | $449K | 1.6% |
| 2 | $46.78 | 50,539 | $2.4M | 8.2% |
| 3 | $46.78 | 49,497 | $2.3M | 8.0% |
| 4 | $46.78 | 49,497 | $2.3M | 8.0% |
| 5 | $46.78 | 50,539 | $2.4M | 8.2% |
| 6 | $46.78 | 9,592 |
| $449K |
| 1.6% |
| 7 | $47.77 | 7,908 | $378K | 1.3% |
| 8 | $47.77 | 40,803 | $1.9M | 6.8% |
| 9 | $47.77 | 40,803 | $1.9M | 6.8% |
| 10 | $47.77 | 41,661 | $2.0M | 6.9% |
| 11 | $47.77 | 41,661 | $2.0M | 6.9% |
| 12 | $47.77 | 7,908 | $378K | 1.3% |
| 13 | $46.19 | 1,826 | $84K | 0.3% |
| 14 | $46.19 | 1,826 | $84K | 0.3% |
| 15 | $46.42 | 8,894 | $413K | 1.4% |
| 16 | $46.42 | 45,894 | $2.1M | 7.4% |
| 17 | $46.42 | 45,894 | $2.1M | 7.4% |
| 18 | $46.42 | 46,861 | $2.2M | 7.5% |
| 19 | $46.42 | 46,861 | $2.2M | 7.5% |
| 20 | $46.42 | 8,894 | $413K | 1.4% |
| 21 | $47.74 | 1,511 | $72K | 0.3% |
| 22 | $47.74 | 293 | $14K | 0.0% |
| 23 | $47.74 | 1,511 | $72K | 0.3% |
| 24 | $47.74 | 1,542 | $74K | 0.3% |
| 25 | $47.74 | 1,542 | $74K | 0.3% |
| 26 | $46.24 | 958 | $44K | 0.2% |
| Total | $46.96 avg | 614,307 | $28.8M | 100% |
| Filing → |